BAFF/BLyS inhibitors: A new prospect for treatment of systemic lupus erythematosus. (Q38013996)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22641424%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

title

BAFF/BLyS inhibitors: A new prospect for treatment of systemic lupus erythematosus (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22641424%20AND%20SRC:MED&resulttype=core&format=json

systemic lupus erythematosus

2 February 2020

main subject

0 references

author

Kirsten A Fairfax

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22641424%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

author name string

Ian R Mackay

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22641424%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Fabienne Mackay

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22641424%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

language of work or name

English

0 references

publication date

29 May 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22641424%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22641424%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

volume

64

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22641424%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

page(s)

595-602

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22641424%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22641424%20AND%20SRC:MED&resulttype=core&format=json

BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator

2 February 2020

cites work

1 reference

BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth

21 January 2018

1 reference

Identification and characterization of a novel cytokine, THANK, a TNF homologue that activates apoptosis, nuclear factor-kappaB, and c-Jun NH2-terminal kinase

21 January 2018

1 reference

Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations

21 January 2018

1 reference

BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population

21 January 2018

1 reference

Ligand-receptor binding revealed by the TNF family member TALL-1

21 January 2018

1 reference

BAFF mediates survival of peripheral immature B lymphocytes

21 January 2018

1 reference

Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA.

21 January 2018

1 reference

B-cell stage and context-dependent requirements for survival signals from BAFF and the B-cell receptor.

21 January 2018

1 reference

Generation and characterization of LymphoStat‐B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator

21 January 2018

1 reference

BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF

21 January 2018

1 reference

B cell-activating factor belonging to the TNF family acts through separate receptors to support B cell survival and T cell-independent antibody formation.

21 January 2018

1 reference

B-cell maturation protein, which binds the tumor necrosis factor family members BAFF and APRIL, is dispensable for humoral immune responses

21 January 2018

1 reference

BCMA is essential for the survival of long-lived bone marrow plasma cells

21 January 2018

1 reference

Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL.

21 January 2018

1 reference

Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor

21 January 2018

1 reference

Transmembrane activator, calcium modulator, and cyclophilin ligand interactor drives plasma cell differentiation in LPS-activated B cells.

21 January 2018

1 reference

TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts

21 January 2018

1 reference

Maturation of marginal zone and follicular B cells requires B cell activating factor of the tumor necrosis factor family and is independent of B cell maturation antigen.

21 January 2018

1 reference

BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2

21 January 2018

1 reference

Development of nephritis but not sialadenitis in autoimmune-prone BAFF transgenic mice lacking marginal zone B cells.

21 January 2018

1 reference

B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations.

21 January 2018

1 reference

Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus

21 January 2018

1 reference

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

Novel evidence-based systemic lupus erythematosus responder index

21 January 2018

1 reference

Treatment of lupus with corticosteroids

21 January 2018

1 reference

Regulated expression of BAFF-binding receptors during human B cell differentiation.

21 January 2018

1 reference

Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus

21 January 2018

1 reference

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus

21 January 2018

1 reference

Maintenance of serological memory by polyclonal activation of human memory B cells.

21 January 2018

1 reference

Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches.

21 January 2018

1 reference

Blockade of B-cell-activating factor suppresses lupus-like syndrome in autoimmune BXSB mice.

21 January 2018

1 reference

TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease

21 January 2018

1 reference

A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses

21 January 2018

1 reference

B cells regulate autoimmunity by provision of IL-10.

21 January 2018

1 reference

T cell costimulation by the TNF ligand BAFF.

21 January 2018

1 reference

Autoimmune disease in Lyn-deficient mice is dependent on an inflammatory environment established by IL-6.

21 January 2018

1 reference

BAFF and MyD88 signals promote a lupuslike disease independent of T cells

21 January 2018

1 reference

How can we reduce the risk of serious infection for patients with systemic lupus erythematosus?

21 January 2018

1 reference

Systemic lupus erythematosus induced by Epstein-Barr virus infection

21 January 2018

1 reference

An Essential Role for BAFF in the Normal Development of B Cells Through a BCMA-Independent Pathway

21 January 2018

1 reference

B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells

21 January 2018

1 reference

Cytokine IL-6 and IL-10 as Biomarkers in Systemic Lupus Erythematosus

21 January 2018

1 reference